相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study
V. Dezentje et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
R. E. Aubert et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
Monique J. Bijl et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Genetic Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 Are not Associated With Prognosis, Endometrial Thickness, or Bone Mineral Density in Japanese Breast Cancer Patients Treated With Adjuvant Tamoxifen
Masatsugu Okishiro et al.
CANCER (2009)
The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells
Xianglin Wu et al.
CANCER RESEARCH (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment
Y. Xu et al.
ANNALS OF ONCOLOGY (2008)
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
Kazuma Kiyotani et al.
CANCER SCIENCE (2008)
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients
William G. Newman et al.
CLINICAL CANCER RESEARCH (2008)
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update
Edoardo Spina et al.
CLINICAL THERAPEUTICS (2008)
Effect of Desvenlafaxine on the Cytochrome P450 2D6 Enzyme System
Sheldon H. Preskorn et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2008)
GRADE:: going from evidence to recommendations
Gordon H. Guyatt et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
TGF beta 2 and T beta RII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells
Miriam B. Buck et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The Rotterdam Study: Objectives and design update
Albert Hofman et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2007)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole
Robert Z. Harris et al.
CLINICAL PHARMACOKINETICS (2007)
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Pia Wegman et al.
BREAST CANCER RESEARCH (2007)
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells
Young Chai Lim et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
James N. Ingle et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial
KJ Pandya et al.
LANCET (2005)
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
SA Nowell et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Inhibition of CYP2D6 activity by bupropion
M Kotlyar et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes
K Nakamura et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
YC Lim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
P Wegman et al.
BREAST CANCER RESEARCH (2005)
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
MD Johnson et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6
M Madeira et al.
DRUG METABOLISM AND DISPOSITION (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients
P Vandel et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans
U Werner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers
MH Skinner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: Mechanism of drug interaction between TCAs and phenytoin
JG Shin et al.
DRUG METABOLISM AND DISPOSITION (2002)
Inhibitory effects of H1-antihistamines on CYP2D6-and CYP2C9-mediated drug metabolic reactions in human liver microsomes
N He et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update
A Hemeryck et al.
CURRENT DRUG METABOLISM (2002)
Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans
É Lessard et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe
J Amchin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors
LL von Moltke et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
CL Loprinzi et al.
LANCET (2000)
Fluvoxamine - An updated review of its use in the management of adults with anxiety disorders
DP Figgitt et al.
DRUGS (2000)
Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
BA Hamelin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Pharmacogenetics of classical and new antipsychotic drugs
K Otani et al.
THERAPEUTIC DRUG MONITORING (2000)
Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions
K Ohyama et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
